Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for

Retrieved on: 2022-12-01 19:48:53

Tags for this article:

Medical specialties

Infectious diseases

Medicine

RTT

Infectious causes of cancer

Vaccine-preventable diseases

Click the tags to see associated articles and topics

Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for. View article details on HISWAI: https://www.elpasoinc.com/bluejay-therapeutics-received-regulatory-clearance-to-initiate-clinical-studies-of-bjt-778-for/article_01c45a1f-ff6e-51df-bf65-1c328fdd69ed.html

Excerpt

... a best-in-class monoclonal antibody against hepatitis B surface ... IgG1 anti-HBs monoclonal antibodies and orally bioavailable liver-targeted ...

Article found on: www.elpasoinc.com

View Original Article